Shareholders at enGene (ENGN) 2026 meeting back directors and auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.
Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares represented at meeting: 56,196,302 shares
Participation rate: 83.89%
Shares outstanding: 66,989,466 shares
+5 more
8 metrics
Shares represented at meeting
56,196,302 shares
Common shares present or represented by proxy at 2026 AGM
Participation rate
83.89%
Portion of 66,989,466 shares outstanding and entitled to vote
Shares outstanding
66,989,466 shares
Common shares outstanding and entitled to vote as of April 28, 2026
Votes for Philip Astley-Sparke
47,112,414 votes
For votes in director election, with 306,821 withheld
Votes for Ronald H.W. Cooper
47,329,848 votes
For votes in director election, with 89,387 withheld
Auditor proposal for votes
56,180,287 votes
Votes for appointment and remuneration of auditor
Auditor proposal withheld
16,015 votes
Votes withheld on appointment and remuneration of auditor
Warrant exercise price
$11.50 per share
Each warrant exercisable for one common share at this price
Key Terms
Annual General Meeting, broker non-votes, Emerging growth company, Proxy Statement, +1 more
5 terms
Annual General Meeting financial
"The 2026 Annual General Meeting of shareholders (the “Annual Meeting”) of enGene Therapeutics Inc."
broker non-votes financial
"Director Nominee | | For | | Withhold | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Proxy Statement regulatory
"which matters are each described in further detail in the Company’s definitive Proxy Statement"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
Inline XBRL technical
"Cover Page Interactive Data File (Formatted as Inline XBRL)."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What was the quorum at enGene Therapeutics (ENGN) 2026 Annual General Meeting?
The quorum was strong, with 56,196,302 common shares represented. This equaled approximately 83.89% of the 66,989,466 shares outstanding and entitled to vote as of the April 28, 2026 record date, indicating broad shareholder participation.
What were the auditor proposal voting results for enGene Therapeutics (ENGN)?
For the proposal on appointment and remuneration of the auditor, shareholders cast 56,180,287 votes for and 16,015 votes withheld. There were no broker non-votes recorded for this item, indicating nearly all represented shares voted on the auditor matter.
When was the record date for enGene Therapeutics (ENGN) 2026 Annual Meeting?
The record date for determining shareholders entitled to vote at the 2026 Annual General Meeting was April 28, 2026. As of that date, 66,989,466 common shares were outstanding and eligible to vote on director elections and the auditor proposal.